Skip to main content

Cancer Moonshot℠ – FY 2017, FY 2018 and FY 2019 Funding Opportunities

Following the authorization of the 21st Century Cures Act, and the appropriation of $300 million in each FY17 and FY18, NCI released the funding opportunities (FOAs) listed below to high research initiatives that align with the efforts of the Cancer Moonshot.

Closed FOAs, FY 2017
BRP Recommendation Title Announcement Number
Adult Immunotherapy Translational Science Network Canine Immunotherapy Trials and Correlative Studies (U01) RFA-CA-17-001
Adult Immunotherapy Translational Science Network Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24) RFA-CA-17-002
Adult Immunotherapy Translational Science Network Consortium for PDAC Translational Studies on the Tumor Microenvironment (U01) RFA-CA-17-015
Adult Immunotherapy Translational Science Network Resource Center for the Consortium for PDAC Translational Studies (U24) RFA-CA-17-016
Adult Immunotherapy Translational Science Network Cancer Immune Monitoring and Analysis Centers (CIMACs) (U24) RFA-CA-17-005
Adult Immunotherapy Translational Science Network Cancer Immunologic Data Common (CIDC) (U24) RFA-CA-17-006
Adult Immunotherapy Translational Science Network Limited Competition: Cancer Immunotherapy Trials Network (CITN) (UM1) RFA-CA-16-501
Adult Immunotherapy Translational Science Network APRC-irAEs Associated with Cancer Immunotherapy (Admin Supp) PA-17-248
Drivers of Childhood Cancers APRC on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp) PA-17-138
New Enabling Technologies PDX Development and Trial Centers (PDTCs) (U54) RFA-CA-17-003
New Enabling Technologies PDX Data Commons and Coordinating Center (PDCCC) for the PDXNet (U24) RFA-CA-17-004
New Enabling Technologies Integration and Validation of Emerging Technologies to Accelerate Cancer Research (R33) RFA-CA-17-023
New Enabling Technologies APTRC for Cancer Research (Admin Supp) PA-17-143
Therapeutic Target Identification to Overcome Resistance Mechanisms of Cancer Drug Resistance and Sensitivity (U54) RFA-CA-17-009
Prevention and Early Detection: Implementation Science Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R01) PAR-16-202
Prevention and Early Detection: Implementation Science Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions (R21) PAR-16-201
Prevention and Early Detection: Implementation Science Dissemination and Implementation Research in Health (R21) PAR-16-236
Prevention and Early Detection: Implementation Science Dissemination and Implementation Research in Health (R01) PAR-16-238
Closed FOAs, FY 2018
BRP Recommendation Title Announcement Number
Adult Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): CIDR (U24) RFA-CA-17-048
Adult Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): DMRC (U24) RFA-CA-17-047
Adult Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention (U01) RFA-CA-17-046
Adult Immunotherapy Translational Science Network Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics (R43/44) PHS2018-1/Topic 372
Adult Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy (U01) RFA-CA-17-045
Cancer Immunotherapy Translational Science Network Pediatric Immunotherapy-Discovery and Development Network (PI-DDN) (U54) RFA-CA-19-003
Cancer Immunotherapy Translational Science Network Pediatric Immunotherapy- Discovery and Development Network (PI-DDN) (U01) RFA-CA-19-004
Drivers of Childhood Cancers Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54) RFA-CA-19-016
Pediatric Immunotherapy Translational Science Network Pediatric Immunotherapy Discovery and Development Network (PI-DDN) (U01) RFA-CA-17-051
Pediatric Immunotherapy Translational Science Network Pediatric Immunotherapy Discovery and Development Network (PI-DDN) (U54) RFA-CA-17-050
Drivers of Childhood Cancers Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54) RFA-CA-17-049
Generation of Human Tumor Atlases Human Tumor Atlas Network: Data Coordinating Center (U24) RFA-CA-17-036
Generation of Human Tumor Atlases Pre-Cancer Atlas (PCA) Research Centers (U2C) RFA-CA-17-035
Generation of Human Tumor Atlases Imaging-Based Tools for Longitudinal and Multi-Dimensional Mapping of the Tumor and its Microenvironment (R43/R44) PHS2018-1/Topic 376
Generation of Human Tumor Atlases Human Tumor Atlas Research Centers (U2C) RFA-CA-17-034
Hereditary Cancers Approaches to Identify & Care for Individuals w/ Inherited Cancer Syndromes (U01) RFA-CA-17-041
Prevention and Screening ACCSIS: Coordinating Center (U24) RFA-CA-17-039
Prevention and Screening ACCSIS (UG3/UH3) RFA-CA-17-038
Symptom Management Research Analyzing & Interpreting Clinician & Patient Adverse Event Data to Understand Tolerability (U01) RFA-CA-17-052
Symptom Management Research Coordinating Center for Research Centers for Improving Management of Symptoms (U24) RFA-CA-17-043
Symptom Management Research Bridging the Guideline Implementation Gap: Glinical Decision-Support to Improve Cancer Symptom Management (R43/R44) PHS2018-1/Topic 377
Symptom Management Research Software Enabling Data Integration from Wearable Sensors to Generate Novel Analytics for Cancer Patients (R43/R44) PHS2018-1/Topic 379
Symptom Management Research Research Centers for Improving Management of Symptoms (UM1) RFA-CA-17-042
Therapeutic Target Identification to Overcome Resistance Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24) RFA-CA-17-044
New Enabling Technologies Minority Patient-Derived Xenograft (PDX) Development and Trial Centers (M-PDTCs) (U54) RFA-CA-17-032
New Enabling Technologies Supplements to Support Collaborations with the PDXNet (Admin Supp) PA-18-496
New Enabling Technologies Diagnostic Imaging for Cancer Immunotherapies (R43/R44) PHS2018-1/Topic 375
New Enabling Technologies Tools and Technologies for Monitoring RNA Modifications (R43) PHS2018-1/Topic 373
New Enabling Technologies Computer Aided Decision Support for Radiation Oncology (R43/R44) PHS2018-1/Topic 380
Closed FOAs, FY 2019
BRP Recommendation Title Announcement Number
New Enabling Technologies Novel Technology Tools to Facilitate Research Using Next Generation Patient-derived Cancer Models (U01 Clinical Trial Not Allowed) RFA-CA-19-055
Prevention and Early Detection: Implementation Science Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01) RFA-CA-19-017
Prevention and Early Detection: Implementation Science Communication and Decision Making for Individuals with Inherited Cancer Syndromes (U01) RFA-CA-19-001
Prevention and Early Detection: Implementation Science Implementation Science for Cancer Control: Developing Centers (P50 Clinical Trial Optional) RFA-CA-19-005
Prevention and Early Detection: Implementation Science Implementation Science for Cancer Control: Advanced Centers (P50 Clinical Trial Optional) RFA-CA-19-006
Cancer Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (UG3/UH3 Clinical Trials Not Allowed) RFA-CA-19-012
Cancer Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): Immuno-engineering to Improve Immunotherapy (i3) Centers (U54 Clinical Trial Not Allowed) RFA-CA-19-013
Cancer Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (U01 Clinical Trial Not Allowed) RFA-CA-19-014
Cancer Immunotherapy Translational Science Network Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy Research Projects (U01 Clinical Trial Not Allowed) RFA-CA-19-015
Prevention and Early Detection: Implementation Science Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS, Second Wave) (UG3/UH3 Clinical Trial Required) RFA-CA-19-018
Therapeutic Target Identification to Overcome Resistance Notice of Special Interest: Administrative Supplements to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN) NOT-CA-19-032
New Enabling Technologies Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet) (Admin Supp Clinical Trial Not Allowed) PA-19-174
Cancer Immunotherapy Translational Science Network Advancing Cancer Immunotherapy by Mitigating Immune-Related Adverse Events (irAE) (U01 Clinical Trial Not Allowed) RFA-CA-19-044
Cancer Immunotherapy Translational Science Network Notice of Special Interest: Administrative Supplements for Activities to Promote Human Immune-Representing Oncology Models     NOT-CA-19-028
New Enabling Cancer Technologies Spatial Sequencing Technologies with Single Cell Resolution for Cancer Research PHS 2020-1/Topic 403
New Enabling Cancer Technologies Subcellular Microscopy and -Omics in Cancer Cell Biology PHS 2020-1/Topic 404 
New Enabling Cancer Technologies Intra-Tumor Sensing Technologies for Tumor Pharmacotyping PHS 2020-1/Topic 405
Prevention and Early Detection Software for Patient Navigation Through the Cancer Care Continuum PHS 2020-1/Topic 406
National Cancer Data Ecosystem Cloud-Based Software for the Cancer Research Data Commons PHS 2020-1/Topic 407
Generation of Human Tumor Atlases Tools and Technologies for Visualizing Multi-Scale Data PHS 2020-1/Topic 408
Network for Patient Engagement Cancer Clinical Trials Recruitment and Retention Tools for Participant Engagement PHS 2020-1/Topic 410
Symptom Management Research Software Enabling Data Integration from Wearable Sensors for Cancer Patients PHS 2020-1/Topic 412
Direct Patient Engagement Network Patient Engagement and Cancer Genome Sequencing (PE-CGS): Research Centers (U2C Clinical Trial Optional) RFA-CA-19-045
Direct Patient Engagement Network  Patient Engagement and Cancer Genome Sequencing (PE-CGS): Coordinating Center (U24 Clinical Trial Not Allowed) RFA-CA-19-046
  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Cancer Moonshot℠ – FY 2017, FY 2018 and FY 2019 Funding Opportunities was originally published by the National Cancer Institute.”